Zighelboim Israel, Powell Matthew A
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri 63110, USA.
Clin Obstet Gynecol. 2011 Jun;54(2):245-55. doi: 10.1097/GRF.0b013e318218c5b8.
A subgroup of endometrial cancer patients with early-stage disease will progress or eventually present with recurrent disease. Multiple risk stratification strategies have been attempted to direct adjuvant therapeutic interventions. Radiation has been the most common form of adjuvant therapy offered to these patients. Unfortunately, its use has not translated into survival improvements. There is growing evidence supporting the use of adjuvant chemotherapy and multimodal interventions for patients with endometrial cancer. This review focuses on the role of adjuvant therapies for patients with early-stage disease with emphasis on future directions for risk stratification and personalized treatment.
一部分早期子宫内膜癌患者会出现疾病进展或最终复发。人们尝试了多种风险分层策略来指导辅助治疗干预。放疗一直是为这些患者提供的最常见的辅助治疗方式。不幸的是,其应用并未转化为生存率的提高。越来越多的证据支持对子宫内膜癌患者使用辅助化疗和多模式干预。本综述重点关注辅助治疗对早期疾病患者的作用,强调风险分层和个性化治疗的未来方向。